A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 1
50
about 4.9 years
18+
15 sites in CA, DC, FL +8
Why this study is shown
What this study is about
Researchers are testing a treatment with glofitamab, gemcitabine, and oxaliplatin for people in the United States who have relapsed or refractory diffuse large B-cell lymphoma. The trial will last about 1798 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Gemcitabine
- 2.Take Glofitamab
- 3.Take Obinutuzumab
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gemcitabine, glofitamab, obinutuzumab, oxaliplatin, tocilizumab (Monoclonal antibody; blocks IL-6 receptor to reduce inflammation)
injection (Injection), injection, intravenous, infusion
Primary: Complete response (CR) rate, Incidence of Adverse Events (AEs)
Secondary: Duration of CR, Duration of response (DOR), Objective response rate (ORR), Overall Survival (OS), Progression-free survival (PFS)
Oncology